

Singapore

3 October 2025

Singapore's retail sales surprised on the upside at 5.2% YoY (0.5% MoM sa) in August 2025

Selena Ling Head of Research and Strategy lingssselena@ocbc.com

Highlights:

- August retail sales were better than expected at 5.2% YoY (0.5% MoM sa), which exceeded the consensus forecast of 4.8% and our forecast of 4.4%. This is also an improvement from the revised 4.6% in July and the fastest pace of growth since February 2024. Auto sales was a big contributor at 8.9% YoY, but other key performing segments also included watches & Jewellery (11.2%), recreational good (9.9%), supermarkets & hypermarkets (8.7%), furniture & household equipment (8.6%), cosmetics/toiletries & medical goods (8.1%) etc. Excluding autos, retail sales also expanded 4.6% YoY, an acceleration from a downwardly revised 3.9% in July. The retail segments that underperformed in August were department stores (-6.5%), food & alcohol (-5.1%), petrol service stations (-5.0%) and wearing apparel & footwear (-1.4%).
- The uptick in discretionary item spending likely reflects an improvement in visitor arrivals in August and domestic consumption may have also picked up after the government upgraded the full-year GDP growth forecast to 1.5-2.5% and as business and consumer confidence improved with the trade deals struck by many countries with the U.S. which resulted in the overall reduction of reciprocal tariffs outside of Singapore which still sees a base tariff level of 10%. Retail sales grew 2.2% YoY for the first eight months of 2025, suggesting that full-year retail sales growth could come in higher at 2.4% YoY. This would be an improvement from the 1.4% seen in retail sales in 2024.
- The S&P Global Singapore PMI also surged from 51.2 in August to 56.4 in **September, marking its eight month of expansion** above the 50 handle. This also coincided with the fastest output growth in a year, aided by new orders and activity as business confidence improved. Consequently, higher purchasing activity contributed to the first expansion in stocks of purchases in five months, suggesting a turnaround from the post-Liberation Day reciprocal tariff announcement. Inventories also saw renewed growth to mitigate supplier delivery times which had extended to the most pronounced pace for the year-to-date. Pressure on supply chains and capacity also intensified. Interestingly, Singaporean private sector firms have supposedly resumed raising staffing levels in September after cutting headcounts in August, to tackle accumulated backlogs and higher new orders. That said, the downside is that overall input prices continued to build, with input price inflation at its highest since January amid both intermediate input prices, wage inflation and utility costs. In turn, companies passed on some cost burdens to clients, resulting in the



sharpest hike in selling prices since January. This bears watching as inflationary pressures may not be as subdued as what was seen in the earlier part of this year and could prove a double-edge sword for domestic businesses even as the business outlook appears to be improving.

For the upcoming October monetary policy review, it may be a close call but MAS may likely lean towards keeping the S\$NEER policy static again at this juncture. Core inflation is subdued, but low base effects from 4Q24 likely means there is slight upside momentum for 4Q25. Overall, headline and core inflation should stay within the official inflation forecast range of 0.5-1.5% YoY this year, albeit likely closer to the lower end of the range. For 2026, I expect both headline and core CPI to rebound above 1% YoY handle as well, so the medium-term inflation outlook is not for a further disinflation trajectory. While GDP growth is expected to decelerate slightly towards 2H25, nevertheless 1H25 performance has been better than expected on frontloading effects as well as resilient domestic momentum. Barring a sharp downturn in the months ahead, full-year GDP growth is likely to exceed the 2% handle as well. Even though the US administration is threatening sectoral tariffs on semiconductors and pharmaceuticals, amongst others, they are still pending implementation and finalisation of tariff levels. As such, there may be a preference to keep some policy powder dry and hold what is possibly the final S\$NEER slope flattening for a later stage when needed such as in 2026. Historically, the S\$NEER slope is only set at a 0% appreciation stance during times of crisis and at this juncture, while the tariff and geopolitical situation is still evolving, market and business sentiments have gradually recovered since the Liberation Day announcement in early April. Moreover, the pharmaceutical tariff appears to be open to concessions if the companies pledge to onshore some production in the US.





-10

Aug-23

Source: Singstat, CEIC, OCBC.

Feb-24

Aug-24

Feb-25

Aug-25

24

25

23

Source: Singstat, CEIC, OCBC

Source: S&P Global PMI. @2025 S&P Global.

30

15 16 17 18

20

21

22

19



Macro Research

Selena Ling

Head of Research & Strategy lingssselena@ocbc.com

Herbert Wong

Hong Kong & Taiwan Economist herberthtwong@ocbc.com

Jonathan Ng

ASEAN Economist jonathanng4@ocbc.com

FX/Rates Strategy

Frances Cheung, CFA
Head of FX & Rates Strategy
francescheung@ocbc.com

Credit Research

Andrew Wong Head of Credit Research wongvkam@ocbc.com

Chin Meng Tee, CFA Credit Research Analyst mengteechin@ocbc.com **Tommy Xie Dongming**

Head of Asia Macro Research xied@ocbc.com

Lavanya Venkateswaran

Senior ASEAN Economist lavanyavenkateswaran@ocbc.com

Ong Shu Yi

ESG Analyst

shuyiong1@ocbc.com

Christopher Wong

FX Strategist

christopherwong@ocbc.com

Ezien Hoo, CFA

Credit Research Analyst ezienhoo@ocbc.com Keung Ching (Cindy)

Hong Kong & Macau Economist cindyckeung@ocbc.com

Ahmad A Enver

ASEAN Economist

ahmad.enver@ocbc.com

Wong Hong Wei, CFA Credit Research Analyst wonghongwei@ocbc.com

This report is solely for information purposes and general circulation only and may not be published, circulated, reproduced or distributed in whole or in part to any other person without our prior written consent. This report should not be construed as an offer or solicitation for the subscription, purchase or sale of the securities/instruments mentioned herein or to participate in any particular trading or investment strategy. Any forecast on the economy, stock market, bond market and economic trends of the markets provided is not necessarily indicative of the future or likely performance of the securities/instruments. Whilst the information contained herein has been compiled from sources believed to be reliable and we have taken all reasonable care to ensure that the information contained in this report is not untrue or misleading at the time of publication, we cannot guarantee and we make no representation as to its accuracy or completeness, and you should not act on it without first independently verifying its contents. The securities/instruments mentioned in this report may not be suitable for investment by all investors. Any opinion or estimate contained in this report is subject to change without notice. We have not given any consideration to and we have not made any investigation of the investment objectives, financial situation or particular needs of the recipient or any class of persons, and accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of the recipient or any class of persons acting on such information or opinion or estimate. This report may cover a wide range of topics and is not intended to be a comprehensive study or to provide any recommendation or advice on personal investing or financial planning. Accordingly, it should not be relied on or treated as a substitute for specific advice concerning individual situations. Please seek advice from a financial adviser regarding the suitability of any investment product taking into account your specific investment objectives, financial situation or particular needs before you make a commitment to purchase the investment product. In the event that you choose not to seek advice from a financial adviser, you should consider whether the investment product mentioned herein is suitable for you. Oversea-Chinese Banking Corporation Limited ("OCBC Bank"), Bank of Singapore Limited ("BOS"), OCBC Investment Research Private Limited ("OIR"), OCBC Securities Private Limited ("OSPL") and their respective related companies, their respective directors and/or employees (collectively "Related Persons") may or might have in the future, interests in the investment products or the issuers mentioned herein. Such interests include effecting transactions in such investment products, and providing broking, investment banking and other financial or securities related services to such issuers as well as other parties generally. OCBC Bank and its Related Persons may also be related to, and receive fees from, providers of such investment products. There may be conflicts of interest between OCBC Bank, BOS, OIR, OSPL or other members of the OCBC Group and any of the persons or entities mentioned in this report of which OCBC Bank and its analyst(s) are not aware due to OCBC Bank's Chinese Wall arrangement. This report is intended for your sole use and information. By accepting this report, you agree that you shall not share, communicate, distribute, deliver a copy of or otherwise disclose in any way all or any part of this report or any information contained herein (such report, part thereof and information, "Relevant Materials") to any person or entity (including, without limitation, any overseas office, affiliate, parent entity, subsidiary entity or related entity) (any such person or entity, a "Relevant Entity") in breach of any law, rule, regulation, guidance or similar. In particular, you agree not to share, communicate, distribute, deliver or otherwise disclose any Relevant Materials to any Relevant Entity that is subject to the Markets in Financial Instruments Directive (2014/65/EU) ("MiFID") and the EU's Markets in Financial Instruments Regulation (600/2014) ("MiFIR") (together referred to as "MiFID II"), or any part thereof, as implemented in any jurisdiction. No member of the OCBC Group shall be liable or responsible for the compliance by you or any Relevant Entity with any law, rule, regulation, guidance or similar (including, without limitation, MiFID II, as implemented in any jurisdiction).

The information provided herein may contain projections or other forward looking statements regarding future events or future performance of countries, assets, markets or companies. Actual events or results may differ materially. Past performance figures are not necessarily indicative of future or likely performance.

Privileged / confidential information may be contained in this report. If you are not the addressee indicated in the message enclosing the report (or responsible for delivery of the message to such person), you may not copy or deliver the message and/or report to anyone. Opinions, conclusions and other information in this document that do not relate to the official business of OCBC Bank, BOS, OIR, OSPL and their respective connected and associated corporations shall be understood as neither given nor endorsed.

Co.Reg.no.: 193200032W